FPF
AERI

FNY Partners Fund’s Aerie Pharmaceuticals AERI Stock Holding History

FNY Partners Fund’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,000
Closed -$48K – 652
2017
Q3 		$48K Buy
+1,000
New +$54.6K 0.01% 295

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FNY Partners Fund's AERI Position: Q4 2017 in Review

FNY Partners Fund sold out of Aerie Pharmaceuticals (AERI) in Q4 2017, closing a stake of 1,000 shares — an estimated $48K sold.

FNY Partners Fund first reported a position in AERI in Q3 2017 and held it in 1 quarter. The position peaked at $48K in Q3 2017. 179 funds tracked by Wall St. Rank hold AERI as of Q4 2017.

  • FNY Partners Fund reported no remaining Aerie Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • FNY Partners Fund sold 1,000 Aerie Pharmaceuticals shares in Q4 2017, an estimated $48K.
  • FNY Partners Fund first reported a position in Aerie Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • FNY Partners Fund's Aerie Pharmaceuticals position peaked at $48K in Q3 2017.
  • 179 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2017.

Based on FNY Partners Fund's 13F filing for Q4 2017, filed 24 Jan 2018.